Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Vertex Pharmaceuticals Inc., consolidated cash flow statement

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net income 3,619,600 3,322,000 2,342,100 2,711,647 1,176,810
Stock-based compensation expense 581,200 491,300 441,400 429,461 360,489
Depreciation and amortization expenses 181,300 148,300 125,600 109,515 106,941
Deferred income taxes (536,500) (275,900) (154,600) 277,341 167,387
(Gains) losses on equity securities 600 149,100 (17,100) (311,937) (197,597)
Increase (decrease) in fair value of contingent consideration (51,600) (57,500) (3,100) 13,100 4,459
Other non-cash items, net 8,400 11,800 14,400 78,832 16,942
Accounts receivable, net (84,100) (358,600) (274,700) (223,444) (225,587)
Inventories (322,900) (136,400) (92,800) (132,014) (64,047)
Prepaid expenses and other assets (545,700) (326,400) (91,800) (297,562) 35,440
Accounts payable 48,700 120,800 31,900 51,276 (22,785)
Accrued expenses 429,400 542,500 305,400 122,198 172,881
Other liabilities 208,900 498,900 16,800 425,092 37,997
Changes in operating assets and liabilities (265,700) 340,800 (105,200) (54,454) (66,101)
Adjustments to reconcile net income to net cash provided by operating activities (82,300) 807,900 301,400 541,858 392,520
Net cash provided by operating activities 3,537,300 4,129,900 2,643,500 3,253,505 1,569,330
Purchases of available-for-sale debt securities (3,786,500) (692,700) (528,200) (431,396) (537,196)
Sales and maturities of available-for-sale debt securities 839,100 920,000 499,300 372,342 475,924
Purchases of property and equipment (200,400) (204,700) (235,000) (259,798) (75,451)
Sale of equity securities 95,100 437,567 94,936
Investment in equity securities and notes receivable (31,000) (47,800) (77,000) (19,327) (39,319)
Payments related to finite-lived intangible assets (58,000)
Payments to acquire businesses, net of cash acquired (295,900) (1,154,212)
Net cash (used in) provided by investing activities (3,141,700) (321,100) (340,900) 99,388 (1,235,318)
Issuances of common stock under benefit plans 134,600 186,300 102,000 264,946 343,244
Repurchases of common stock (427,600) (1,425,400) (539,136) (186,020)
Payments in connection with common stock withheld for employee tax obligations (226,100) (172,000) (135,900) (200,271) (5,995)
Payments on finance leases (44,900) (85,500) (47,000) (42,275) (39,185)
Proceeds from finance leases 22,600 13,251 10,046
Other financing activities 1,800 3,500 5,700 (1,796) 4,683
Net cash provided by (used in) financing activities (562,200) (67,700) (1,478,000) (505,281) 126,773
Effect of changes in exchange rates on cash 26,900 (29,200) (13,400) 20,552 1,643
Net increase (decrease) in cash, cash equivalents and restricted cash (139,700) 3,711,900 811,200 2,868,164 462,428
Cash, cash equivalents and restricted cash, beginning of period 10,512,000 6,800,100 5,988,900 3,120,681 2,658,253
Cash, cash equivalents and restricted cash, end of period 10,372,300 10,512,000 6,800,100 5,988,845 3,120,681

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Vertex Pharmaceuticals Inc. net cash provided by operating activities increased from 2021 to 2022 but then slightly decreased from 2022 to 2023.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Vertex Pharmaceuticals Inc. net cash (used in) provided by investing activities increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Vertex Pharmaceuticals Inc. net cash provided by (used in) financing activities increased from 2021 to 2022 but then slightly decreased from 2022 to 2023.